4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Bronchiectasis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 179 ongoing clinical trials involving Bronchiectasis
Of the 179 trials,91 trials are in Phase III
Furthermore, 55 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Bronchiectasis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Bronchiectasis, a respiratory condition. The largest number of ongoing clinical trials for Bronchiectasis is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions involved in Bronchiectasis-related drug trials.

Bronchiectasis related clinical trialsponsors

Shanghai Pulmonary Hospital, Zambon Co SpA, and Guangzhou Institute of Respiratory Diseases are a few notable clinical trial sponsors involved in Bronchiectasis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Bronchiectasis

Imipenem and cilastatin sodium (Primaxin, Tienam, Zienam), Carbocisteine (Mucodyne DS / Mucodyne), and Amoxicillin (Amoxil/Clamoxyl/Larotid/Amoxybid/Amoxil BD/Amoxil S/Amoxil SF/ Amoxil D, Delamoxyle)are among the key marketed drugs involving Bronchiectasis.

Imipenem and cilastatin sodium (Primaxin, Tienam, Zienam) is a fixed dose combination drug consisting of broad-spectrum antibacterial agents. It functions via Dipeptidyl Peptidase 1 (Cathepsin C or Cathepsin J or Dipeptidyl Transferase or DPPI or CTSC or EC 3.4.14.1) Inhibitor; Penicillin Binding Protein (PBP) Inhibitor mechanism of action. It is formulated as injectable powder solution and solution for intramuscular and intravenous route of administration. Imipenem and cilastatin sodium is marketed for the treatment of Urinary Tract Infections, Bacterial Conjunctivitis, Cholangitis, Cholecystitis, Acute Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Bacterial Pneumonia, Bacterial Vaginosis, Gonorrhea, Syphilis, Bacterial (Pyogenic) Meningitis, Appendicitis, Abscess, Liver Abscess, Bacteremia, Lower Respiratory Tract Infections, and Ventilator Associated Pneumonia (VAP). Bronchiectasis was first approved in 1984 and is marketed globally including the US, the UK, France, Germany, China, and Japan byMerck & Co Inc and its subsidiaries.

Carbocisteine is a mucolytic agent. It acts during the mucous gel phase, by breaking up the disulfide bonds in glycoproteins and favours expectoration by modifying mucous secretions.  It is formulated as tablets, granules, syrup and dry syrup for oral route of administration. Carbocisteine is indicated in upper respiratory tract inflammation (pharyngitis, laryngitis), acute bronchitis, bronchial asthma, chronic bronchitis, bronchiectasis, pulmonary tuberculosis, chronic sinusitis drainage and drainage of exudative otitis media. Carbocisteine was first approved in 1986 and is marketed in Japan byKYORIN Holdings Inc.